))
Interview with Steven Yatomi-Clarke CEO and Managing Director, Prescient Therapeutics
Manage episode 421240257 series 3551735
Sisällön tarjoaa Chris Titley. Chris Titley tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Today I chat with Steven Yatomi-Clarke around Prescient Therapeutics.
Steven delves in to the history of the business , the growth of the portfolio and the importance of PTX-100 to the business.
Steven talks about the importance of PTX-100 , the process of design, the testing, how it works and also how meaningful the future results are.
Steven also talks about the timeline of broader advances in medicine, the time, the effort as well as trends in AI.
This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.
9 jaksoa
Jaa
